摘要
目的评价莫西沙星序贯治疗社区获得性肺炎(CAP)住院患者的疗效和安全性。方法北京大学深圳医院2009年1月-2010年12月收治的186例CAP住院患者随机分为2组,莫西沙星序贯组(序贯组)和莫西沙星静脉滴注组(对照组),序贯组(86例)在治疗当天开始给予莫西沙星注射液400mg/d静脉滴注,每日1次,3～5d后改为口服莫西沙星片剂400mg/d,总疗程7～14d;对照组(88例)给予莫西沙星注射液400mg/d静脉滴注,每日1次,总疗程7～14 d。结果经剔除部分患者后,两组均无严重不良反应,两组安全性比较差异无统计意义,临床疗效:序贯组有效率87.2%,对照组有效率89.8%。细菌学疗效比较:治疗后序贯组细菌清除率为92.1%,对照组细菌清除率为95.7%,两组差异无统计学意义(P>0.05)。结论莫西沙星对住院CAP患者疗效可靠,安全性好。序贯治疗组与全程静脉滴注相仿,对于可以口服的患者可以替代全程静脉滴注作为住院CAP患者的治疗方案。
Objective To evaluate the efficacy and safety of sequential moxifloxacin therapy in treatment of hospitalized patients with community-acquired pneumonia（CAP）.Methods The 186 patients with community-acquired pneumonia who were hospitalized during January 2009 and December 2010 were randomized to receive two different moxifloxacin regimens.The patients in the control group received moxifloxacin by intravenous infusion,400 mg once daily for 7-10 days.The patients in sequential therapy group received moxifloxacin by intravenous infusion 400 mg once daily for 3-5 days,followed by oral administration at the same dose.The total treatment duration was also 7-14 days.Results Eighty-six patients in sequential group and 88 patients in control group completed the study.No serious adverse drug reaction was reported in either group.The safety profile did not show any significant difference between the two groups（P0.05）.The clinical efficacy rate was 87.2%in sequential group, and 89.8%in the control group.The bacterial eradication rate was 92.1%in sequential group and 95.7%in the control group, respectively.Comparison between groups did not show any significant difference（P0.05）.Conclusions Moxifloxacin is effective and safe in the treatment of local hospitalized CAP patients.The sequential therapy is similar to full intravenous therapy. It may be a useful alternative therapy for those CAP patients who can take the drug orally.
出处
《中国感染与化疗杂志》
CAS
2011年第5期335-338,共4页
Chinese Journal of Infection and Chemotherapy
关键词
莫西沙星
社区获得性肺炎
住院
序贯治疗
moxifloxacin
community-acquired pneumonia
inpatients
sequential therapy
